Course Objectives
Upon completion of this course, participants should be able to:
- Examine new evidence for understanding the pathophysiology in nonexudative age-related macular degeneration
- Examine new evidence for predicting disease progression in nonexudative age-related macular degeneration
- Evaluate emerging therapies for the treatment of nonexudative age-related macular degeneration with a particular focus on complement inhibitors and the population most likely to benefit once these drugs are approved
- Evaluate therapies targeting novel disease pathways being investigated in early-stage clinical trials for nonexudative age-related macular degeneration
- Evaluate the clinical use of available anti-VEGF drugs for exudative ocular diseases
- Provide an update on the next generation of anti-VEGF therapies recently approved and currently in development
- Evaluate the benefits and limitations of different imaging technologies in the diagnosis and clinical management of macular and retinal diseases
- Incorporate the latest advances in artificial intelligence, specifically machine learning, for the diagnosis and treatment of retinal diseases